These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15191946)

  • 21. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.
    Mavrakanas T; Bounameaux H
    Pharmacol Ther; 2011 Apr; 130(1):46-58. PubMed ID: 21185864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of ximelagatran in the treatment of venous thromboembolism.
    Schulman S
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():18-24. PubMed ID: 15812200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new era for anticoagulants.
    Franchini M; Mannucci PM
    Eur J Intern Med; 2009 Oct; 20(6):562-8. PubMed ID: 19782914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
    Agnelli G; Sonaglia F; Becattini C
    Curr Pharm Des; 2005; 11(30):3885-91. PubMed ID: 16305519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ximelagatran--a promising new drug in thromboembolic disorders.
    Petersen P
    Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New anticoagulants: current status and future potential.
    Weitz JI; Crowther MA
    Am J Cardiovasc Drugs; 2003; 3(3):201-9. PubMed ID: 14727932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.
    Martí-Fàbregas J; Mateo J
    Cerebrovasc Dis; 2009; 27 Suppl 1():111-9. PubMed ID: 19342840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?
    Mousa SA; Abdel-Razeq HN
    Cardiovasc Drug Rev; 2005; 23(4):331-44. PubMed ID: 16614732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
    Eriksson BI; Dahl OE
    Drugs; 2004; 64(6):577-95. PubMed ID: 15018589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New anticoagulants for venous thromboembolic disease.
    Chang P
    IDrugs; 2004 Jan; 7(1):50-7. PubMed ID: 14730467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel anticoagulant therapy: principle and practice.
    Mousa SA
    Methods Mol Biol; 2010; 663():157-79. PubMed ID: 20617417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral factor Xa and direct thrombin inhibitors: a clinical perspective.
    Thethi I; Lewis B; Fareed J
    J Burn Care Res; 2012; 33(4):453-61. PubMed ID: 22269826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism.
    Haas S
    Drugs; 2004; 64 Suppl 1():7-16. PubMed ID: 15586623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.